The Prescription Only Medicines (Human Use) Amendment Order 1999

• Citation: S.I. 1999/1044
• Sections: 2

Section 1 Citation, commencement and interpretation

(1) This Order may be cited as the Prescription Only Medicines (Human Use) Amendment Order 1999 and shall come into force on 22nd April 1999.

(2) In this Order, “the principal Order ” means the Prescription Only Medicines (Human Use) Order 1997 .

Section 2 Amendment of Schedule 1 to the principal Order

In Schedule 1 to the principal Order (which specifies substances which if included in medicinal products make those products prescription only medicines and exemptions from restrictions on the sale and supply of prescription only medicines)—

(a) in relation to the substance Aspirin , the entries in columns 2, 3 and 5 numbered “(1)” are re-numbered “(2)”, the entry in column 3 numbered “(2)” is re-numbered “(3)”; and, before those entries re-numbered “(2)”, there are inserted the following entries—

in column 2—

(1) 75mg

in column 3—

(1) Non-effervescent tablets and capsules

in column 5—

(1) The quantity sold or supplied in one container or package shall not exceed 100

The quantity of non-effervescent tablets, capsules or a combination of both sold or supplied to a person at any one time shall not exceed 100

(b) in relation to the substance Beclomethasone Dipropionate , in the entry in column 5, for “5,600 mcg” there is substituted “20,000 mcg”;

(c) in relation to the substance Hydrocortisone , the entry in each of columns 2 and 5 is, and the entries in column 3 are, numbered “(2)”; and, before the entries in columns 2, 3 and 5, there are inserted the following entries—

in column 2—

(1) 0.5 per cent

in column 3—

(1) External

For use in combination with Nystatin of maximum strength 3.0 per cent for intertrigo

For use in adults and children not less than 10 years

in column 5—

(1) Container or package containing not more than 15g of medicinal product

(d) in relation to the substance Nystatin, there are inserted the following entries—

in column 2—

3.0 per cent

in column 3—

External

For use in combination with Hydrocortisone of maximum strength 0.5 per cent for intertrigo

For use in adults and children not less than 10 years

in column 5—

Container or package containing not more than 15g of medicinal product

(e) there is inserted in column 1, at the appropriate place in the alphabetical order of the entries in that column, each of the following substances—

Candesartan Cilexetil

Lornoxicam

Losartan Potassium

Nebivolol Hydrochloride

Nisoldipine

Propiverine Hydrochloride

Quetiapine Fumarate

Tacalcitol Monohydrate